Uncategorized
Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients
DAEJEON, South Korea--(BUSINESS WIRE)-- #196170KQ--Alteogen completed a Phase 1 clinical trial of Eylea® Biosimilar (ALT-L9) in wet AMD patients at 4 major hospitals in Korea.